Gaboxadol

Drug Profile

Gaboxadol

Alternative Names: Gaboxadole; LU 02-030; LU 0203; MK 0928; OV 101; THIP

Latest Information Update: 14 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Max Planck Institute of Psychiatry
  • Developer Lundbeck A/S; Ovid Therapeutics
  • Class Anaesthetics; Analgesics; Anorectics; Antidepressants; Antiepileptic drugs; Hypnosedatives; Isoxazoles; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angelman syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Angelman syndrome
  • Phase I Fragile X syndrome
  • Preclinical Epilepsy
  • Discontinued Insomnia; Major depressive disorder

Most Recent Events

  • 11 Aug 2017 Ovid plans a clinical trial for Angelman syndrome or Fragile X syndrome (In children)
  • 10 Apr 2017 Phase-I clinical trials in Angelman syndrome (In adolescents) in USA (PO)
  • 10 Apr 2017 Phase-I clinical trials in Fragile X syndrome (In adolescents) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top